HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

INTRODUCTION: Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate the safety/efficacy of ledipasvir/sofosbuvir (LDV/...

Descripción completa

Detalles Bibliográficos
Autores principales: Huhn, Gregory D., Ramgopal, Moti, Jain, Mamta K., Hinestrosa, Federico, Asmuth, David M., Slim, Jihad, Goldstein, Deborah, Applin, Shauna, Ryu, Julie H., Jiang, Shuping, Cox, Stephanie, Das, Moupali, Nguyen-Cleary, Thai, Piontkowsky, David, Guyer, Bill, Rossaro, Lorenzo, Haubrich, Richard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988963/
https://www.ncbi.nlm.nih.gov/pubmed/31995556
http://dx.doi.org/10.1371/journal.pone.0224875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988963/
https://www.ncbi.nlm.nih.gov/pubmed/31995556
http://dx.doi.org/10.1371/journal.pone.0224875

Ejemplares similares